Munich-based medtech company Hema.to has raised €3.6 million in a funding round led by LUMO Labs, with participation from Bayern Kapital, US angel investors, and existing backers such as Elaia Partners, Heal Capital, and HTGF. The company specializes in AI-driven solutions for blood cancer diagnostics and immune disease detection. With the rising demand for more efficient diagnostic tools, Hema.to aims to streamline laboratory workflows and improve early disease detection. The funding will be used to enhance its AI-powered cytometry technology and support its expansion efforts in Europe and beyond.
Hema.to’s approach builds on earlier advancements in automated hematology. Similar AI-driven diagnostic tools have been developed in the past, but many required extensive manual oversight or lacked broad clinical validation. The company’s database, containing over 600,000 files from leading medical centers, enhances its ability to detect diseases such as leukemia and lymphoma. Unlike some previous initiatives, Hema.to’s CE-marked AI models are already in use across European labs, with further certification processes underway. The company has also expanded its collaborations to institutions in the US and Israel, setting it apart from competitors.
How Does Hema.to’s AI Cytometry Work?
Hema.to’s technology employs artificial intelligence to interpret cytometry data, significantly reducing the time required for blood sample analysis. Traditional cytometry testing can take up to 20 minutes per sample, whereas Hema.to’s AI system can process the same data in approximately one minute. This efficiency allows laboratories to handle larger sample volumes while minimizing the risk of misdiagnosis.
By analyzing immune profiles, the system also supports personalized treatment approaches. The company’s software is cloud-based, enabling real-time collaboration among medical professionals. Currently, its AI models are being used in hospitals and laboratories across Europe, with plans to expand into additional markets.
What Will the New Investment Be Used For?
The fresh funding will support Hema.to’s efforts to further develop its AI platform, pursue additional European certifications, and conduct clinical studies. The company also plans to expand its diagnostic capabilities to cover a wider range of immune disorders. Additionally, part of the investment will be allocated to scaling commercial operations.
“At Hema.to, we like to say that we want to ‘make your blood speak’,” said CEO and co-founder Karsten Miermans. “Blood data holds the key to the immune system, but at present, life-threatening illnesses like leukemia or lymphoma can be overlooked in blood analysis—even when the data that indicates otherwise is right there.”
Bayern Kapital, one of the investors in this round, manages significant venture capital funding in the DACH region, supporting numerous startups. The firm’s participation signals confidence in Hema.to’s potential for growth and impact in clinical diagnostics.
LUMO Labs, known for funding impact-driven startups, also highlighted the potential benefits of Hema.to’s AI-powered solution.
“Through our investments in emerging technologies in Digital Health and Medtech, we want to improve the quality of life of patients and professionals and relieve the ever-increasing strain on public healthcare,” said LUMO Labs Founding Partner Sven Bakkes.
The growing role of AI in medical diagnostics reflects a broader trend toward automation in healthcare. By reducing manual workload, AI solutions aim to optimize efficiency while maintaining diagnostic accuracy. However, widespread adoption will depend on regulatory approvals and continued validation through clinical studies. Hema.to’s expansion into immune disorder detection could further position it as a key player in this sector. As the company progresses, its ability to integrate AI-driven diagnostics into routine clinical workflows will determine its long-term success.
